Cargando…

PB1753: SYNERGISTIC ANTITUMOR EFFECT OF CHIDAMIDE WITH VENETOCLAX IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BY SUPPRESSING PI3K/AKT SIGNALING

Detalles Bibliográficos
Autores principales:	Song, D., Song, C., Ge, Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430031/ http://dx.doi.org/10.1097/01.HS9.0000849868.89934.c9

Ejemplares similares

PB1753: EVALUATION OF IMMUNOPHENOTYPIC CHARACTERISTICS OF RESIDUAL CELLS IN COMPARISON WITH NORMAL HEMATOGONES AND MATURE CELLS IN CHILDREN WITH B-CELL LYMPHOBLASTIC LEUKEMIA
por: Karnabeda, Oksana, et al.
Publicado: (2023)

PB1729: RETROSPECTIVE STUDY OF MAINTENANCE THERAPY WITH CHIDAMIDE AFTER TRANSPLANTATION FOR PATIENTS WITH HIGH RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Wang, Xueying, et al.
Publicado: (2023)

PB1736: CLINICAL ANALYSIS OF VENETOCLAX-BASED IN THE TREATMENT OF ADULT RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Jing, et al.
Publicado: (2023)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Hou, Yue, et al.
Publicado: (2023)

PB1749: APOPTOTIC EFFECT OF FLUMATINIB COMBINED WITH BCL2 INHIBITOR ON PH+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Gu, Y., et al.
Publicado: (2022)

PB1862: VENETOCLAX AND AZACITIDINE THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE RENAL IMPAIRMENT
por: Naka, Ryosuke, et al.
Publicado: (2023)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

PB1817: THE ADDITION OF ZALCITABINE TO ACUTE MYELOID LEUKEMIA TREATMENT MAY IMPROVE AZACITIDINE AND VENETOCLAX COMBINATION
por: Sofía, Álvarez-Galeano, et al.
Publicado: (2023)

PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Vakonaki, E., et al.
Publicado: (2022)

PB1877: EFFECTS OF VENETOCLAX-BASED COMBINATIONS FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN CLINICAL SETTINGS
por: Park, Young Seob, et al.
Publicado: (2023)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023)

PB1726: HEARING STATUS OF SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Mahfouz, Asmaa, et al.
Publicado: (2023)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
por: Kayser, Sabine, et al.
Publicado: (2023)

PB1745: SURVIVAL AND PROGNOSTIC FACTORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN OMAN.
por: Almamari, Moza, et al.
Publicado: (2023)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

PB1757: NOVEL THERAPEUTIC STRATEGY TARGETING CELLULAR REDOX SYSTEMS USING DIMETHYL FUMARATE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Kawaguchi, Shin-Ichiro, et al.
Publicado: (2023)

PB1754: HOMOZYGOUS DELETION OF ETV6: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA OR PRECURSOR T-LYMPHOBLASTIC LYMPHOMA
por: Álvarez, Miguel Ángel Perera, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE
por: Amato, Viviana, et al.
Publicado: (2023)

PB1748: DIFFERENTIAL IRON HOMEOSTASIS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN VITRO MODELS
por: Capelletti, M. M., et al.
Publicado: (2022)

PB1717: CD19-NEGATIVE B- ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT CHALLENGES?
por: Siala, Nour, et al.
Publicado: (2023)

PB1722: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSIS AND TREATMENT CHALLENGES
por: Siala, Nour, et al.
Publicado: (2023)

PB1746: EVOLUTION OF SARS-COV-2 INFECTION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
por: Guerbouj, Hamida Khémiri, et al.
Publicado: (2023)

PB1734: SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ECUADOR. AN ANALYSIS OF THE REAL WORLD
por: Sabando, Brenner, et al.
Publicado: (2023)

PB1810: SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Long, Huideng, et al.
Publicado: (2023)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Kuzmina, Elena, et al.
Publicado: (2023)

PB1750: REARRANGEMENTS OF T-CELL RECEPTOR (TCR) LOCI IN CHILDREN WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Lizcova, L., et al.
Publicado: (2022)

PB1766: PROGNOSTIC SIGNIFICANCE OF ACTIVIN A IN ADULT EGYPTIAN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Azzazi, M., et al.
Publicado: (2022)

PB1954: PROGNOSTIC ANALYSIS OF GENE MUTATIONS ON TIME-TO-FIRST TREATMEN IN 93 NEWLY DIAGNOSED CHRONIC LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Xiang, Xixi, et al.
Publicado: (2023)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

PB1755: CASPASE 8, CASPASE 10 AND FAS GENE POLYMORPHISMS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Lourou, M., et al.
Publicado: (2022)

PB1767: OUTCOME OF RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA SINGLE CENTER EXPERIENCE
por: Siala, N., et al.
Publicado: (2022)

PB1723: CLINICAL AND GENETIC CHARACTERISTICS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH STIL-TAL1 FUSION
por: Chang, Soon Hee, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3kkstafekejg34vd5r4p2m1mm8